

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6100785

| | |
|---|---------------------------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| Name | Execution Date |
| INFACARE PHARMACEUTICAL CORPORATION | 05/24/2019 |
| RECEIVING PARTY DATA | |
| Name: | MALLINCKRODT PHARMA IP TRADING D.A.C. |
| Street Address: | COLLEGE BUSINESS & TECHNOLOGY PARK |
| Internal Address: | CRUISERATH, BLANCHARDSTOWN |
| City: | DUBLIN |
| State/Country: | IRELAND |
| Postal Code: | 15 |
| PROPERTY NUMBERS Total: 1 | |
| Property Type | Number |
| Application Number: | 16864510 |
| CORRESPONDENCE DATA | |
| Fax Number: | (816)421-5547 |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | |
| Email: | drule@shb.com |
| Correspondent Name: | SHOOK HARDY & BACON LLP |
| Address Line 1: | 2555 GRAND BOULEVARD |
| Address Line 4: | KANSAS CITY, MISSOURI 64108 |
| ATTORNEY DOCKET NUMBER: | 12653.342625 |
| NAME OF SUBMITTER: | ROBERT D. CHISHOLM |
| SIGNATURE: | /ROBERT D. CHISHOLM/ |
| DATE SIGNED: | 05/11/2020 |
| Total Attachments: 2 | |
| source=324016_No2_Reel049274_Frame0943#page1.tif | |
| source=324016_No2_Reel049274_Frame0943#page2.tif | |

ASSIGNMENT AGREEMENT

WHEREAS, InfaCare Pharmaceutical Corporation, a Delaware corporation located at 8 Neshaminy Interplex, Trevese, PA 19053 ("Assignor"), is the owner of the entire right, title and interest in and to the patents and patent applications described below and the corresponding inventions as described and claimed therein (collectively "Patent Properties"):

| Status | Application | File date | Patent No. | Issue Date | Title |
|-----------|-------------|------------|------------|------------|---|
| Published | 13/691,677 | 11/30/2012 | | | Methods For Treating Hyperbilirubinemia With Stannosoporphin |
| Granted | 10/812,156 | 3/29/2004 | 7,375,216 | 5/20/2008 | Preparation Of Metal Mesoporphyrin Halide Compounds |
| Granted | 13/435,868 | 3/30/2012 | 8,735,574 | 5/27/2014 | Methods For Synthesizing Metal Mesoporphyrins |
| Granted | 14/253,710 | 4/15/2014 | 9,181,285 | 11/10/2015 | Methods For Synthesizing Metal Mesoporphyrins |
| Granted | 14/875,141 | 10/5/2015 | 9,688,705 | 6/27/2017 | Methods For Synthesizing Metal Mesoporphyrins |
| Granted | 15/343,967 | 11/4/2016 | 9,902,745 | 2/27/2018 | High-Purity Large-Scale Preparation Of Stannosoporphin |
| Granted | 11/867,559 | 10/4/2007 | 7,960,371 | 6/14/2011 | High-Purity Large-Scale Preparation Of Stannosoporphin |
| Granted | 12/968,651 | 12/15/2010 | 8,530,458 | 9/10/2013 | High-Purity Large-Scale Preparation Of Stannosoporphin |
| Granted | 14/019,513 | 9/5/2013 | 8,835,416 | 9/16/2014 | High-Purity Large-Scale Preparation Of Stannosoporphin |
| Granted | 14/460,080 | 8/14/2014 | 9,107,927 | 9/18/2015 | High-Purity Large-Scale Preparation Of Stannosoporphin |
| Granted | 14/793,921 | 7/8/2015 | 9,517,239 | 12/13/2016 | High-Purity Large-Scale Preparation Of Stannosoporphin |
| Granted | 10/453,815 | 6/3/2003 | 6,818,763 | 11/16/2004 | Preparation Of Metal Mesoporphyrin Halide Compounds |
| Granted | 11/957,317 | 12/14/2007 | 7777028 | 8/17/2010 | Preparation Of Metal Mesoporphyrin Compounds |
| Granted | 12/833,873 | 7/9/2010 | 8178664 | 5/15/2012 | Preparation Of Metal Mesoporphyrin Compounds |
| Granted | 15/867,900 | 1/11/2018 | 10,273,255 | 4/30/2019 | High-Purity Large-Scale Preparation Of Stannosoporphin |
| Published | 16/125,190 | 9/7/2018 | | | Methods For Synthesizing Metal Mesoporphyrins |
| Pending | 16/300,362 | 11/9/2018 | | | Methods For Treating Hyperbilirubinemia With Stannosoporphin And Phototherapy |
| Pending | 16/298,603 | 3/11/2019 | | | High-Purity Large-Scale Preparation Of Stannosoporphin |

AND WHEREAS, Mallinckrodt Pharma IP Trading D.A.C., an Irish designated activity company located at College Business &

Technology Park, Cruiserath, Blanchardstown, Dublin 15, Ireland ("Assignee"), is desirous of acquiring the entire right, title and interest in and to the Patent Properties and in and to any letters patent that may be granted therefor in the United States and in any and all foreign countries.

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged. ASSIGNOR hereby sell, assign and transfer unto said ASSIGNEE, their entire worldwide right, title and interest in and to the Patent Properties, and to any and all letters patent which may be granted as a result thereof in the United States of America, in the territorial possessions of the United States of America and in any and all foreign countries, and to any and all divisions, reissues and continuations thereof, including the right to sue and recover damages for past infringement, the right to file foreign applications directly in the name of ASSIGNEE, the right to claim priority rights deriving from the Patent Properties to which said foreign applications are entitled by virtue of international convention, treaty or otherwise, said inventions and all letters patent on said inventions to be held and enjoyed by ASSIGNEE and its successors and assigns as fully and entirely as the same would have been held and enjoyed by ASSIGNOR had this sale, assignment and transfer not been made.

This Assignment is effective as from: December 21, 2017

Executed the 24 day of May 2019 (Execution date)

Infacare Pharmaceutical Corporation
By: Carlynn Davis
Name: Carlynn Davis
Title: Attorney-in-fact

Mallinckrodt Pharma IP Trading D.A.C.
By: Carlynn Davis
Name: Carlynn Davis
Title: Attorney-in-fact